sorafenib has been researched along with Acoustic Neurinoma, Bilateral in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bulman, M; Evans, DGR; Freemont, AJ; Linder, C; Mangham, DC; Smith, MJ; Wallace, A | 1 |
| Ammoun, S; Evans, DG; Hanemann, CO; Hayward, C; Hilton, DA; Streeter, A | 1 |
| Hamilton, J; Hong, DS; Ketonen, LM; Kurzrock, R; McCutcheon, IE; Slopis, J; Subbiah, V | 1 |
1 review(s) available for sorafenib and Acoustic Neurinoma, Bilateral
| Article | Year |
|---|---|
Sarcoma in neurofibromatosis 2: case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Delayed Diagnosis; Diagnosis, Differential; Doxorubicin; Fatal Outcome; Humans; Male; Neoplasm Grading; Neurofibromatosis 2; Neurofibromin 2; Palliative Care; Retroperitoneal Neoplasms; Sarcoma; SMARCB1 Protein; Sorafenib; Spinal Neoplasms; Young Adult | 2019 |
1 trial(s) available for sorafenib and Acoustic Neurinoma, Bilateral
| Article | Year |
|---|---|
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Child; Child, Preschool; Drug Synergism; Erlotinib Hydrochloride; Female; Humans; Indoles; Male; Molecular Targeted Therapy; Neurofibromatosis 2; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome; Valproic Acid; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
1 other study(ies) available for sorafenib and Acoustic Neurinoma, Bilateral
| Article | Year |
|---|---|
Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2.
Topics: Adult; Antineoplastic Agents; Blotting, Western; Caspase 3; Cyclin D1; Humans; Immunohistochemistry; Leukocytes, Mononuclear; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Targeted Therapy; Neurofibromatosis 2; Proto-Oncogene Proteins c-akt; Receptor, Platelet-Derived Growth Factor beta; Ribosomal Protein S6; Sorafenib | 2019 |